Optimizing Neurotherapy for
Multiple Sclerosis and
Parkinson’s Disease

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period April 30, 2010 through April 30, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

2.5 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of and strategies for early diagnosis and management of multiple sclerosis and Parkinson’s disease .

Release Date:

April 30, 2010

Expiration Date:

April 30, 2012

Intended Audience:

This complimentary CME educational activity is designed for all physicians, nurses, NPs, academicians, pharmacists, researchers, investigators, and program directors managing, referring, and/or consulting on patients with MS and/or PD.

We welcome neurology-focused clinicians with expertise in the fields of general neurology, multiple sclerosis, Parkinson’s disease, geriatrics, internal medicine, and from other specialties and services who are part of the multidisciplinary team caring for patients with MS, PD, and related conditions.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant
from Teva Neuroscience

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

University of Massachusetts Medical School designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

C. Warren Olanow, MD, FRCPC – Program Chairman
Henry P. and Georgette Goldschmidt Professor and Chairman Emeritus,
Department of Neurology
Professor, Department of Neuroscience
Director, Robert and John M. Bendheim Parkinson’s Disease Center
Mount Sinai School of Medicine
New York, NY

Consulting: Boehringer Ingelheim; Ceregene, Inc., Merck Serono International, SA; Novartis; Solvay Pharmaceuticals, Inc.; and Teva Neuroscience


Howard L. Zwibel, MD
Founding Medical Director, Emeritus
Neuroscience Consultants
Comprehensive Multiple Sclerosis Center in affiliation with the National Multiple Sclerosis
Center Coral Gables, Florida
Baptist Health Doctors Hospital MS Center
Coral Gables, FL

Consultant: TEVA, Acorda
Speaker’s Bureau: TEVA, Acorda, Novartis


Douglas R. Jeffery, MD, PhD
Associate Professor
Department of Neurology
Wake Forest University Baptist Medical Center
Winston-Salem, NC

Consultant: TEVA, Bayer, Biogen, Serono, Pfizer, GSK, Novartis
Speaker’s Bureau: TEVA, Bayer, Biogen, Acorda, Novartis
Grant/Research Support: Bayer, Serono, Biogen, TEVA, Novartis

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewers Denise Leary and Richard Aghababian, MD have nothing to disclose.

Educational Objectives:

For Parkinson’s Disease

• Be better able to understand the design, rationale, and interpretation of early start trials for Parkinson’s Disease (PD) and their implications for clinical practice
• Be better able to implement into their clinical practice, evidence-based pharmacologic strategies that have the potential for modifying the disease course of PD and delay disease progression
• Be better able to understand the evidence basis and clinical trial data for the foundation role of selective MAO-B inhibitors as part of multimodal management of PD
• Be better able to understand potential mechanisms and evidence for why certain neurotherapeutic interventions may provide preclinical neuroprotection, slowing of disease progression, and a rationale for early treatment in PD
• Be better able to identify PD patients early in their clinical course, and assess nonmotor treatment triggers to prompt early therapy in PD
• Be better able to understand the complexities, trial designs, results, dosing implications, and front-line clinical Implications of delayed start trials in PD
• Be better able to implement therapies that have the potential to slow the clinical progression in PD
• Better understand how advances in basic science and new clinical studies suggest landscape changes in pharmacologic management of PD

For Multiple Sclerosis

• Better understand the date, expert analysis, and evidence supporting the foundation role of immunomodulation therapy (IMT) for long-term efficacy, safety, neuronal preservation, and disability mitigation in MS
• Be better able, in the clinical setting, to balance efficacy benefits against safety risks to achieve long-term efficacy with IMT
• Become more clinically skilled at applying evidence and conclusions from long-term follow-up trials to the front lines of MS practice
• Be better able to apply first-line therapy with IMTs to specific patient subgroups with MS
• Be better able to understand the efficacy and safety issues associated with immunosuppressive agents for MS, with a focus on patient selection, monitoring, risks for infection, and mechanisms of action
• Become more clinically proficient, based on clinical trial data, at optimizing long-term functional and financial outcomes in RRMS with IMT
• Be better able to assess the enduring efficacy, reduction of disability metrics (EDSS, MSSS, and MSFC), and maintenance of quality of life (QOL) measures associated with MS therapies
• Be better able to use neuroimaging in MS and better understand its utility for monitoring disease progression, timing of intervention, and choice of neurotherapeutic strategies
• Be better able to evaluate clinical results and monitoring effects of IMTs with current and evolving scanning techniques
  

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes.
  

Disclaimer:

Copyright © 2011 Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2011 Resources, LLC All rights reserved.